Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
ZR-MTX for PIOL Phase II Trial
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
- Status
- RECRUITING
- Phase
- PHASE2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Status
- RECRUITING
- Phase
- PHASE3
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
- Status
- RECRUITING
- Phase
- PHASE2
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2